613 related articles for article (PubMed ID: 29121979)
21. Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.
Kaul U; Mansoor AH
Indian Heart J; 2012; 64(1):54-9. PubMed ID: 22572427
[TBL] [Abstract][Full Text] [Related]
22. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
[TBL] [Abstract][Full Text] [Related]
23. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Parker WA; Storey RF
Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
[TBL] [Abstract][Full Text] [Related]
24. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
25. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
[TBL] [Abstract][Full Text] [Related]
27. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
28. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Daffara V; Pergolini P; Rolla R; Marino P; Bellomo G; Carriero A; De Luca G;
Vascul Pharmacol; 2017 Aug; 93-95():42-47. PubMed ID: 28433569
[TBL] [Abstract][Full Text] [Related]
30. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Baber U; Dangas G; Cohen DJ; Gibson CM; Mehta SR; Angiolillo DJ; Pocock SJ; Krucoff MW; Kastrati A; Ohman EM; Steg PG; Badimon J; Zafar MU; Chandrasekhar J; Sartori S; Aquino M; Mehran R
Am Heart J; 2016 Dec; 182():125-134. PubMed ID: 27914492
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
32. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Clemmensen P; Dridi NP; Holmvang L
Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
[TBL] [Abstract][Full Text] [Related]
34. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
Guimarães PO; Franken M; Tavares CAM; Silveira FS; Antunes MO; Bergo RR; Joaquim RM; Hirai JCS; Andrade PB; Pitta FG; Mariani J; Nascimento BR; de Paula JET; Silveira MS; Costa TAO; Dall'Orto FTC; Serpa RG; Sampaio FBA; Ohe LN; Mangione FM; Furtado RHM; Sarmento-Leite R; Monfardini F; Assis SRL; Nicolau JC; Sposito AC; Lopes RD; Onuma Y; Valgimigli M; Angiolillo DJ; Serruys PW; Berwanger O; Bacal F; Lemos PA
EuroIntervention; 2023 Jul; 19(4):e323-e329. PubMed ID: 37306039
[TBL] [Abstract][Full Text] [Related]
35. Aspirin-Free Strategies After Complex PCI: Type of P2Y
Gragnano F; Calabrò P
JACC Cardiovasc Interv; 2024 May; 17(9):1131-1133. PubMed ID: 38749593
[No Abstract] [Full Text] [Related]
36. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
37. Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials.
Shoji S; Kuno T; Ueyama H; Takagi H; Briasoulis A; Kim HS; Koo BK; Kang J; Watanabe H; Kimura T; Kohsaka S
J Cardiol; 2024 May; 83(5):338-347. PubMed ID: 37562542
[TBL] [Abstract][Full Text] [Related]
38. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
Valgimigli M; Gragnano F; Branca M; Franzone A; da Costa BR; Baber U; Kimura T; Jang Y; Hahn JY; Zhao Q; Windecker S; Gibson CM; Watanabe H; Kim BK; Song YB; Zhu Y; Vranckx P; Mehta S; Ando K; Hong SJ; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Calabrò P; Jüni P; Mehran R;
JAMA Cardiol; 2024 May; 9(5):437-448. PubMed ID: 38506796
[TBL] [Abstract][Full Text] [Related]
39. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Vranckx P; Valgimigli M; Windecker S; Steg PG; Hamm C; Jüni P; Garcia-Garcia HM; van Es GA; Serruys PW
EuroIntervention; 2016 Nov; 12(10):1239-1245. PubMed ID: 26606735
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Study).
Pufulete M; Harris J; Sterne JAC; Johnson TW; Lasserson D; Mumford A; Doble B; Wordsworth S; Benedetto U; Rogers CA; Loke Y; Pithara C; Redwood S; Reeves BC
BMJ Open; 2019 Jun; 9(6):e029388. PubMed ID: 31167875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]